engleski

Use of the automated Cobas 4800 system in cervical cancer screening

Cervical cancer is the second most common malignancy in women worldwide, with about 490, 000 newly registered cases every year. In Europe, there are about 50, 000 new cases, and about 25, 000 deaths yearly, and in Croatia with population of 4.4 million there are on average 355 new cases and about 100 deaths each year. Persistent infection with human papillomavirus (HPV) is the principal cause of cervical cancer in women, with HPV implicated in greater than 99 percent of cervical cancers worldwide. Of about 40 known sexually transmitted HPV types, approximately 15 have been established as oncogenic or high-risk types (hrHPV) in epidemiologic studies. HPV-16 and HPV-18 account for about 70% of all cervical cancers, and women who are infected with those two hrHPV types have the greatest risk for developing cervical intraepithelial neoplasia (CIN) or cancer. There are two clinically validated and approved HPV technologies available to prevent cervical cancer: HPV vaccination and HPV testing. While HPV vaccines are tools for primary prevention strategy, HPV tests are tools for secondary prevention, since they are used to prevent HPV infection and neoplasias of progressing to invasive cancer. The Roche Cobas 4800 test is FDA approved HPV test which simultaneously detect 12 hrHPV types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as pooled result, as well as HPV-16 and HPV-18 individually. In the Zagreb region during the seven-month period a total of 2, 979 cervical cell specimens were tested by using the automated Cobas 4800 system. HPV was detected in 1, 210 (40.6%) of samples, while HPV-16 and/or HPV-18 were detected in 464 (38.4%) of HPV-positive women. The prevalence of hrHPV increased with the severity of cervical lesions. Recent data confirm the increased accuracy of HPV testing over conventional cytologic Pap testing. Ability of identification of HPV-16 and HPV-18 during routine testing is very important because women with persistent infection with one of these types are at risk of high-grade CIN also when cervical pre-malignant lesions are missed by the Pap test.

HPV infection; cervical cancer; screening

nije evidentirano